Raltegravir and zidovudine (DrugBank: Zidovudine, Raltegravir)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
26 | HTLV-1関連脊髄症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02655471 (ClinicalTrials.gov) | July 1, 2017 | 16/11/2015 | Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection | Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study | HTLV-I Infections;Tropical Spastic Paraparesis | Drug: Raltegravir and Zidovudine | Universidad Peruana Cayetano Heredia | Merck Sharp & Dohme Corp. | Completed | 18 Years | N/A | All | 10 | Early Phase 1 | Peru |